Biography
Caroline Elvig is an associate in Weil’s Antitrust group. Her practice focuses on regulatory approval for mergers and acquisitions as well as government investigations and antitrust litigations in both U.S. District Court and state courts. She works on matters across a wide range of industries, including software/technology, pharmaceuticals, agriculture, and finance.
Caroline maintains an active pro bono practice, that includes working with the Center for Reproductive Rights and Floridians for Reproductive Freedom to challenge laws in North Dakota and Florida.
Caroline received her J.D. from the University of Virginia School of Law where she served on the Editorial Board of the Journal of Law & Politics. She received her B.A., summa cum laude, in History and a minor in Business from Texas A&M University.
Caroline’s recent experience includes serving on Weil teams representing:
- Regeneron Pharmaceuticals in a jury trial win involving monopolization and tort claims against Amgen relating to actions it took against Regeneron’s cholesterol drug, Praluent.
- Bruker (f/k/a NanoString Technologies, Inc.) in a patent and antitrust litigation against 10x Genomics, Inc. and Harvard College.
- Goldman Sachs in Omega Healthcare Management Services’ investment by OTPP
- Siete Foods in its $1.2 billion sale to PepsiCo.
- Brookfield Asset Management and its affiliates in multiple matters, including:
- The $775 million acquisition of data center provider Cyxtera.
- Brookfield’s creation of a joint venture with Digital Realty and Reliance Industries to develop and operate data centers in India.
- Meta Platforms (f/k/a Facebook) in its acquisition of Within.